Dukes-McEwan J, Garven K E, Lopez Alvarez J, Oliveira P, Motskula P F, Willis R
Department of Small Animal Clinical Science, School of Veterinary Science, Leahurst Campus, University of Liverpool, Chester High Road, Neston, CH64 7TE, UK.
MBM Veterinary Group, 21 Hill Street, Kilmarnock, KA3 1HF, UK.
J Small Anim Pract. 2022 Apr;63(4):275-285. doi: 10.1111/jsap.13455. Epub 2021 Dec 13.
To assess the diagnostic accuracy of two cardiac biomarker assays (N-terminal pro-BNP , Troponin I) in detecting dilated cardiomyopathy in Dobermanns.
Dobermanns undergoing cardiac biomarker testing were screened by echocardiography and Holter monitoring, then assigned to a group: normal, equivocal, arrhythmia form of dilated cardiomyopathy, echocardiographic form of dilated cardiomyopathy or both. Some were reassessed to identify final status. Initial cardiac biomarker results were compared to final status. Receiver operating characteristic curves were used to identify area under the curve and corresponding sensitivity (Se), specificity (Sp) for different cut-offs (CO) for each cardiac biomarker.
A total of 118 Dobermanns with cardiac biomarker data had echocardiography/Holter assessment. Repeat assessment was carried out in 47 Dobermanns after 394.5 ±151.0 days. Seventeen dogs changed group between initial and final status. The final status of 59 was normal, nine were equivocal and 50 had dilated cardiomyopathy (prevalence 42.4%). Of the dilated cardiomyopathy group, 25 had dilated cardiomyopathy-both, 13 dilated cardiomyopathy-echocardiography and 12 dilated cardiomyopathy-Holter. Receiver operating characteristic area under the curve=0.807 for N-terminal proBNP (Se 0.69 and Sp 0.81) and 0.873 for high-sensitivity cardiac Troponin I (Se 0.77 and Sp 0.86). When both Se and Sp were optimised for all forms of dilated cardiomyopathy, N-terminal proBNP cut-off was 626 pmol/L (Se and Sp 0.79) and high-sensitivity cardiac Troponin I cut-off was 0.056 ng/mL (Se and Sp 0.84). Receiver operating characteristic area under the curve was higher for dilated cardiomyopathy-echocardiography (NT-proBNP 0.883; high-sensitivity cardiac Troponin I 0.907) than dilated cardiomyopathy-Holter.
Cardiac biomarker screening may be useful to select Dobermanns which would benefit from further assessment by echocardiography and Holter.
评估两种心脏生物标志物检测方法（N 端前脑钠肽、肌钙蛋白 I）在检测杜宾犬扩张型心肌病方面的诊断准确性。
对接受心脏生物标志物检测的杜宾犬进行超声心动图和动态心电图监测筛查，然后分为以下几组：正常、可疑、心律失常型扩张型心肌病、超声心动图型扩张型心肌病或两者皆有。部分犬只进行重新评估以确定最终状态。将初始心脏生物标志物检测结果与最终状态进行比较。使用受试者工作特征曲线确定曲线下面积以及每种心脏生物标志物在不同临界值（CO）下对应的灵敏度（Se）、特异性（Sp）。
共有 118 只具有心脏生物标志物数据的杜宾犬接受了超声心动图/动态心电图评估。47 只杜宾犬在 394.5±151.0 天后进行了重复评估。17 只犬在初始和最终状态之间改变了分组。最终状态为 59 只正常，9 只可疑，50 只患有扩张型心肌病（患病率 42.4%）。在扩张型心肌病组中，25 只患有扩张型心肌病（两者皆有），13 只患有超声心动图型扩张型心肌病，12 只患有动态心电图型扩张型心肌病。N 端前脑钠肽的受试者工作特征曲线下面积 = 0.807（Se 0.69，Sp 0.81），高敏肌钙蛋白 I 的曲线下面积 = 0.873（Se 0.77，Sp 0.86）。当针对所有形式的扩张型心肌病优化 Se 和 Sp 时，N 端前脑钠肽的临界值为 626 pmol/L（Se 和 Sp 0.79），高敏肌钙蛋白 I 的临界值为 0.056 ng/mL（Se 和 Sp 0.84）。超声心动图型扩张型心肌病的受试者工作特征曲线下面积（NT - proBNP 0.883；高敏肌钙蛋白 I 0.907）高于动态心电图型扩张型心肌病。
心脏生物标志物筛查可能有助于选择那些将从超声心动图和动态心电图进一步评估中获益的杜宾犬。
